Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
3.420
-0.300 (-8.06%)
At close: Feb 20, 2026, 4:00 PM EST
3.430
+0.010 (0.29%)
After-hours: Feb 20, 2026, 7:59 PM EST
Recursion Pharmaceuticals Revenue
Recursion Pharmaceuticals had revenue of $5.18M in the quarter ending September 30, 2025, a decrease of -80.16%. This brings the company's revenue in the last twelve months to $43.69M, down -32.98% year-over-year. In the year 2024, Recursion Pharmaceuticals had annual revenue of $58.84M with 32.00% growth.
Revenue (ttm)
$43.69M
Revenue Growth
-32.98%
P/S Ratio
40.74
Revenue / Employee
$54,611
Employees
800
Market Cap
1.78B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 58.84M | 14.26M | 32.00% |
| Dec 31, 2023 | 44.58M | 4.73M | 11.88% |
| Dec 31, 2022 | 39.84M | 29.67M | 291.46% |
| Dec 31, 2021 | 10.18M | 6.22M | 156.89% |
| Dec 31, 2020 | 3.96M | 1.64M | 70.85% |
| Dec 31, 2019 | 2.32M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 2.41B |
| Innoviva | 388.52M |
| Vericel | 258.72M |
| Stoke Therapeutics | 205.63M |
| Syndax Pharmaceuticals | 111.30M |
| Precigen | 6.31M |
RXRX News
- 2 days ago - Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25 - GlobeNewsWire
- 2 days ago - Applied Digital, Recursion Pharmaceuticals Stocks Drop. Blame Nvidia. - Barrons
- 4 weeks ago - Recursion Pharmaceuticals, Inc. (RXRX) Presents at 28th Annual Needham Growth Conference Transcript - Seeking Alpha
- 5 weeks ago - Recursion Pharmaceuticals, Inc. (RXRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 6 weeks ago - Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 2 months ago - 3 Small AI Plays to Buy for 2026 - Benzinga
- 2 months ago - Recursion Pharmaceuticals: Upgrading To Buy - My Most Surprising Call Of 2025 - Seeking Alpha
- 2 months ago - What's Happening With RXRX Stock? - Forbes